Detalles de la búsqueda
1.
Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting.
Ther Adv Med Oncol
; 15: 17588359231152847, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36743523
2.
Characteristics, management, and healthcare resources of patients with advanced non-small-cell lung cancer surviving 5 years after nivolumab treatment initiation: A national database analysis.
Respir Med Res
; 84: 101051, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37897879
3.
Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France.
J Med Econ
; 25(1): 691-699, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35587018
4.
Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.
Lung Cancer
; 172: 65-74, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36007281
5.
Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.
Lung Cancer
; 157: 40-47, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33980420
6.
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study.
Oncoimmunology
; 9(1): 1744898, 2020 04 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33457089
Resultados
1 -
6
de 6
1
Próxima >
>>